Table 4 Risk of ovarian cancer recurrence and CA-125 serum concentration changes 3 and 6 months after therapy in subgroups of patients. NACT-Neoadjuvant chemotherapy
Subgroups of patients | Risk of ovarian cancer recurrence - HR (p) | |||||
|---|---|---|---|---|---|---|
CA-125 changes 3 months after therapy [U/ml] | CA-125 changes 6 months after therapy [U/ml] | |||||
< 0 | 0–5 | > 5 | < 0 | 0–5 | > 5 | |
FIGO 1&2 (n = 52) | 1.00 | 0.97 (p = 0.97) | 6.95 (p = 0.085) | 1.00 | 1.57 (p = 0.516) | 4.71 (p = 0.09) |
FIGO 3&4 (n = 116) | 1.00 | 1.42 (p = 0.145) | 6.65 (p < 0.0001) | 1.00 | 1.51 (p = 0.11) | 6.33 (p < 0.0001) |
Grade 2&3 (n = 152) | 1.00 | 1.28 (p = 0.2885) | 7.07 (p < 0.0001) | 1.00 | 1.28 (p = 0.3388) | 4.99 (p < 0.0001) |
Serous (n = 124) | 1.00 | 1.34 (p = 0.2247) | 8.53 (p < 0.0001) | 1.00 | 1.32 (p < 0.2955) | 5.17 (p < 0.0001) |
NACT (n = 26) | 1.00 | 1.71 (p = 0.34) | 4975 (p = 0.99) | 1.00 | 1.22 (p = 0.698) | 2.83 (p = 0.11) |
Bevacizumab (n = 32) | 1.00 | 1.62 (p = 0.29) | – | 1.00 | 1.48 (p = 0.383) | 10.1 (p < 0.008) |
Optimal cytoreduction (< 1 cm) (n = 145) | 1.00 | 1.34 (p = 0.4) | 6.93 (p < 0.014) | 1.00 | 1.64 (p = 0.179) | 7.24 (p < 0.0001) |